Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples|
|Study Start Date:||August 2001|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
- To establish a demographic database to evaluate the efficacy of medical interventions in patients and relatives who carry BRCA1 and 2 mutations and to compare these outcomes to patients who do not carry a BRCA1 or 2 mutation.
- To obtain blood samples from patients who undergo genetic testing to a) evaluate the incidence of genetic modifier polymorphisms involved in the development of cancer in BRCA1 and 2 mutation carriers and to compare this incidence to non-BRCA 1 and 2 carriers. b) to understand the interaction of genetic modifiers and BRCA1 and 2 in the development of cancer. c) to determine the effect of environmental influences on the incidence of polymorphisms in genetic modifiers and on the penetrance of BRCA1 and 2 mutations by linking information from our demographic database to blood samples and
- To obtain tumor tissue from BRCA1 and 2 carriers to utilize for gene expression studies.
- To establish a cohort of sporadic breast cancer patients, or women with no family history of cancer in a first degree relative, to serve as a comparison group to women with strong family history of breast cancer.
- To establish a cohort of healthy volunteers without personal or family history of cancer to serve as a comparison group to women with sporadic and familial breast cancer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01034033
|Contact: Meredith Mills||(650) email@example.com|
|United States, California|
|Stanford University School of Medicine||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Meredith Mills 650-724-5223 firstname.lastname@example.org|
|Principal Investigator: James M Ford|
|Sub-Investigator: Hanlee P. Ji|
|Sub-Investigator: Vandana Bhardwaj Sharma|
|Sub-Investigator: Patrick O. Brown|
|Sub-Investigator: Maria Gramatges|
|Sub-Investigator: Allison Walsh Kurian|
|Principal Investigator:||James M Ford||Stanford University|